✦ LIBER ✦

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

✍ Scribed by Cappuzzo, Federico; Ardizzoni, Andrea; Soto-Parra, Hector; Gridelli, Cesare; Maione, Paolo; Tiseo, Marcello; Calandri, Cesare; Bartolini, Stefania; Santoro, Armando; Crinò, Lucio

Book ID: 118571147
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 270 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)00189-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-633 Non-small cell lung cancer (NSCLC)

P-633 Non-small cell lung cancer (NSCLC) patients with undetectable epidermal growth factor receptor (EGFR) expression respond poorly to ZD1839 (Iressa)

✍ Polowy, Clayton R.; Coon, John S.; Leslie, William T.; DiNunno, Lucio; Lukic, Iv 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 184 KB

ZD 1839 in patients with brain metastase

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

✍ Cappuzzo, F; Calandri, C; Bartolini, S; Crinò, L 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 102 KB

‘Targeting’ the epidermal growth factor

‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)

✍ William Pao; Vincent A. Miller; Mark G. Kris 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer

✍ Sae-Won Han; Pil Gyu Hwang; Doo Hyun Chung; Dong-Wan Kim; Seock-Ah Im; Young Tae 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 351 KB 👁 1 views

## Abstract Gefitinib has shown meaningful antitumor activity with tolerable toxicity in chemotherapy‐refractory NSCLC in previous studies. Moreover, EGFR expression failed to show a correlation with response. In an attempt to identify predictive markers of response, we have investigated the tumora

P-612 Gefitinib (Iressa, ZD1839) is acti

P-612 Gefitinib (Iressa, ZD1839) is active as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer (NSCLC)

✍ Argiris, Athanassios; Mittal, Namrata; Masters, Gregory 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Combination therapy with ZD1839 (‘Iressa

Combination therapy with ZD1839 (‘Iressa’) and docetaxel in patients with advanced or metastatic non-small-cell lung cancer (nsclc): preliminary safety results of an open-label, pilot trial

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 137 KB